within Pharmacolibrary.Drugs.ATC.L;

model L01CE01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00023000000000000003,
    adminDuration  = 600,
    adminMass      = 1.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.032299999999999995,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.026199999999999998,
    k12             = 18.1,
    k21             = 18.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01CE01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Topotecan is a topoisomerase I inhibitor used primarily in the treatment of various cancers including ovarian cancer, small cell lung cancer, and cervical cancer. It is an antineoplastic agent that interferes with the replication of DNA in cancer cells. Topotecan is an approved drug and is administered commonly via intravenous infusion or orally.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult cancer patients following intravenous administration.</p><h4>References</h4><ol><li><p>Requejo, F, et al., &amp; Schaiquevich, P (2023). Pharmacokinetics of Orbital Topotecan After Ophthalmic Artery Chemosurgery and Intravenous Infusion in the Swine Model. <i>Investigative ophthalmology &amp; visual science</i> 64(12) 3–None. DOI:<a href=\"https://doi.org/10.1167/iovs.64.12.3\">10.1167/iovs.64.12.3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37656475/\">https://pubmed.ncbi.nlm.nih.gov/37656475</a></p></li><li><p>Davies, BE, et al., &amp; Beijnen, JH (1997). The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog. <i>Pharmaceutical research</i> 14(10) 1461–1465. DOI:<a href=\"https://doi.org/10.1023/a:1012189225880\">10.1023/a:1012189225880</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9358562/\">https://pubmed.ncbi.nlm.nih.gov/9358562</a></p></li><li><p>Cheng, Y, et al., &amp; Zhou, L (2024). Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES). <i>Lung cancer (Amsterdam, Netherlands)</i> 188 107455–None. DOI:<a href=\"https://doi.org/10.1016/j.lungcan.2023.107455\">10.1016/j.lungcan.2023.107455</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38224653/\">https://pubmed.ncbi.nlm.nih.gov/38224653</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01CE01;
